Audited Financial Results - 2013-14

6 downloads 5056 Views 483KB Size Report
May 30, 2014 ... API DMF/COS filings in other key regulated markets ... Moxifloxacin Hydrochloride Tablets 400mg - Anti-Infective – Final (Earlier Tentative). 4.

NEWS RELEASE 30th May 2014, Hyderabad, India.

FY 2013-14 Audited Financials Q4FY14 ` Crores

Q4FY13 ` Crores

Y-o-Y Variance

FY 13-14 ` Crores

FY 12-13 ` Crores

Y-o-Y Variance

Consolidated Net Operating Income

2329.8

1570.4

48.4%

8099.8

5855.3

38.3%

Operating Profit (EBIDTA) before Fx

743.0

240.0

209.6%

2132.8

889.1

139.9%

PBT before Fx (Profit)

631.4

153.3

311.9%

1735.6

537.5

222.9%

Key consolidated financial highlights for Q4 FY2013-14: • • • • • • • •

Total Operating Income up by 48.4% to `2329.8 Crores (`1570.4 Crores) Operating Profit (EBIDTA) before Fx improves to 31.9% (15.3%) Operating Profit (EBIDTA) before Fx up 209.6% to ` 743.0 Crores (`240.0 Crores) PBT before Fx up by 311.9% to ` 631.4 Crores (`153.3 Crores) PAT up by 362.1% to `501.8 Crores (`108.6 Crores) Basic & diluted EPS is ` 17.22 and `17.20 Formulation Sales up by 75.8% to ` 1613.5Crores (`918.0 Crores) API Sales up by 13.2% to ` 754.8 Crores (`666.8 Crores)

Key consolidated financial highlights for FY2013-14: • Total Operating Income up by 38.3% to `8099.8 Crores (`5855.3Crores) • Operating Profit (EBIDTA) before Fx improves to 26.3% (15.2%) • Operating Profit (EBIDTA) before Fx up 139.9% to `2132.8 Crores (`889.1 Crores) • PBT before Fx up by 222.9% to `1735.6 Crores (`537.5 Crores) • PAT up by 299.1% to ` 1172.9Crores (`293.9 Crores) • Basic & diluted EPS is `40.27 and `40.22 • Formulation Sales up by 58.8% to `5378.5Crores (`3387.2 Crores) • API Sales up by 12.9% to `2864.2 Crores (`2536.2 Crores) • Formulations Sales constitute 65.3% (57.2%) and API 34.7% (42.8%) of gross sales • Board has inter-alia considered and approved second interim dividend @ 175% (`1.75/- per equity share of the face value of `1/- each) in addition to the interim dividend of 125% (`1.25/- per equity share of the face value of `1/- each), aggregating to 300% (`3.00/- per equity share of the face value of `1/- each) for the year 2013-14. The Board do not recommend any further dividend for the year 2013-14

Commenting on the Company’s performance, Mr. N. Govindarajan, Managing Director of the company said:

“We have reported yet another year of commendable business deliveries resulting in strong growth in revenues and profits. We continue to invest in building a quality organization as we focus on optimizing the mix of products and markets in line with capacities to drive operating efficiencies. We are also making steady progress on our differentiated product offerings especially with the parenterals gaining traction in advanced geographies” Domestic and Export breakup of Gross Sales (Stand Alone) : Particulars Domestic Export Total

Q1FY14 378.3 1265.9 1644.2

Q2FY14 405.1 1226.4 1631.5

Q3FY14 500.5 1436.8 1937.3

Q4FY14 448.3 1594.4 2042.7

FY 13-14 1732.2 5523.5 7255.7

Page 1 of 4

(` in Crores) FY 12-13 1493.3 4043.0 5536.3

Change +16.0% +36.6% +31.1%

Segmental Breakup of Sales (Consolidated): Particulars USA Europe RoW ARVs Formulations

(` in Crores) FY 12-13 1752.6 467.9 416.4 750.3 3387.2

Q1FY14 624.8 173.9 110.0 191.8 1100.5

Q2FY14 730.8 170.6 93.9 233.1 1228.4

Q3FY14 931.2 150.8 133.7 220.4 1436.1

Q4FY14 1116.0 176.8 125.8 194.9 1613.5

FY 13-14 3402.8 672.1 463.4 840.2 5378.5

3.0

6.3

1.7

5.5

16.5

76.0

(78.3%)

222.2 216.3 208.5 647.0

242.9 206.6 268.4 717.9

258.3 217.5 268.7 744.5

254.4 235.0 265.4 754.8

977.8 875.4 1011.0 2864.2

765.2 937.3 833.7 2536.2

+27.8% (6.6%) +21.3% +12.9%

Dossier Income SSPs Cephs Non-Betalactum Active Ingredients

Change +94.2% +43.6% +11.3% +12.0% +58.8%

Global Regulatory Filings: Filings

Cumulative Filings as on 31st Mar 2013 269 172

Filings made during Q4FY14 28 5

Filings made during FY14 67 9

Cumulative Filings as on 31st Mar 2014 336 181

ANDAs (USA) DMFs (USA) Formulations Dossiers in other key advanced markets 1753 57 244 1997 (incl. Multiple registration into EU. SA, Australia, Canada) API DMF/COS filings in other key regulated markets 2117 23 120 2237 Patents 532 10 29 561 Following approvals in USA (191 cumulative approvals, net of 10 withdrawals during the year including 26 tentative by USFDA), Australia South Africa (70 cumulative approvals by MCC-SA) and Canada (48 cumulative approvals by Health Canada)) were received during the quarter ended 31st March 2014: USA 1. Repaglinide Tablets USP 0.5mg, 1mg and 2mg - Anti-diabetic – Final (Earlier Tentative) 2. Atazanavir Sulfate Capsules 100mg, 150mg, 200mg and 300mg – ARV - Tentative 3. Moxifloxacin Hydrochloride Tablets 400mg - Anti-Infective – Final (Earlier Tentative) 4. Memantine Hydrochloride Tablets 5mg and 10mg – Alzheimer - Tentative South Africa 1. Betahistine Tablets 8mg, 16mg, 24mg 2. Bisoprolol Tablets 2.5mg, 5mg, 10mg 3. Ampicillin powder for Injection 250mg, 500mg, 1g 4. Alendronic Acid Tablets 10mg, 70mg

Canada 5. Carvedilol Tablets 3.125mg,6.25mg,12.5mg, 25mg 6. Omeprazole Delayed release Capsules 10mg, 20mg 7. Montelukast chewable tablet 4mg, 5mg

About Aurobindo Pharma Limited: Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries. For further information, please contact: Investor Relations Aurobindo Pharma Limited Corporate Office: WaterMark Building, Level-1 Plot No.11, Survey No. 9 Kondapur, Hitech City, Hyderabad

Phone: 040-66725000 / 66725401 Email: [email protected] Website : www.aurobindo,.com

Reg Office: Plot No. 2, Maitrivihar Ameerpet, Hyderabad

Page 2 of 4

Page 3 of 4

Page 4 of 4